{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:23:23Z","timestamp":1771269803589,"version":"3.50.1"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2015-1272_s_999_w2aab2b8c69b1b7b1aab1c15b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p> We evaluated the effect of kidney glomerular function on serum concentrations of human epididymis protein 4 (HE4) using creatinine (Cr), cystatin C (CysC) and related chronic kidney disease epidemiology collaboration (CKD-EPI) equations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1272_s_998_w2aab2b8c69b1b7b1aab1c15b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p> We enrolled 101 women aged \u226456 years with a glomerular filtration rate (GFR) (estimated by CKD-EPI eGFR<jats:sub>Cr<\/jats:sub>) ranging from 60 to 120 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, free of any disease and biological and life-style factors known to influence serum HE4 concentrations, and we measured serum Cr, CysC and HE4 concentrations. Cr and CysC values were included in the three CKD-EPI equations to obtain GFR estimates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1272_s_997_w2aab2b8c69b1b7b1aab1c15b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p> A statistically significant increase in HE4 median concentrations was detected in subjects with an eGFR<jats:sub>Cr<\/jats:sub> between 60 and 74 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> when compared with those with an eGFR &gt;90 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> (54.2 vs. 42.2 pmol\/L, p=0.003). Regression models showed that CysC measurement per se and eGFR<jats:sub>CysC<\/jats:sub> were the most sensitive markers to catch HE4 increases due to a mild decrease in renal function [adjusted r<jats:sup>2<\/jats:sup>, 0.38 (p=0.00003) and 0.37 (p=0.0004), respectively]. By assuming baseline CysC and eGFR<jats:sub>CysC<\/jats:sub> at 0.80 mg\/L and 101.5 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, an increase of 0.10 mg\/L in CysC concentrations and a decrease of 10 mL\/min of eGFR<jats:sub>CysC<\/jats:sub> implied an average (\u00b1SE) increase in serum HE4 concentrations of 9.2 (\u00b11.2) and 8.8 (\u00b11.1) pmol\/L, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1272_s_996_w2aab2b8c69b1b7b1aab1c15b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p> Our study shows that a better estimate of the effect of GFR on serum HE4 is obtained by measuring CysC in serum or using CKD-EPI eGFR<jats:sub>CysC<\/jats:sub> equation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2015-1272","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T17:00:56Z","timestamp":1461085256000},"page":"1629-1634","source":"Crossref","is-referenced-by-count":6,"title":["Cystatin C provides a better estimate of the effect of glomerular filtration rate on serum human epididymis protein 4 concentrations"],"prefix":"10.1515","volume":"54","author":[{"given":"Simona","family":"Ferraro","sequence":"first","affiliation":[{"name":"Clinical Pathology Unit, \u2018Luigi Sacco\u2019 University Hospital, Milan, Via G.B. Grassi 74, 20157 Milano, Italy , Phone: +39 02 3904 2766, Fax: +39 02 50319835"},{"name":"Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pasqualetti","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy"},{"name":"Clinical Pathology Unit, \u2018Luigi Sacco\u2019 University Hospital, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Carnevale","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy"},{"name":"Clinical Pathology Unit, \u2018Luigi Sacco\u2019 University Hospital, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Panteghini","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy"},{"name":"Clinical Pathology Unit, \u2018Luigi Sacco\u2019 University Hospital, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"2023033109501727150_j_cclm-2015-1272_ref_001_w2aab2b8c69b1b7b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol 2013;66:273\u201381.","DOI":"10.1136\/jclinpath-2012-201031"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_002_w2aab2b8c69b1b7b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Ferraro S, Panteghini M. Is serum human epididymis protein 4 ready for prime time? Ann Clin Biochem 2014;51:128\u201336.","DOI":"10.1177\/0004563213500657"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_003_w2aab2b8c69b1b7b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Braga F, Ferraro S, Mozzi R, Panteghini M. The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer. Clin Chem Lab Med 2014;52:1625\u201331.","DOI":"10.1515\/cclm-2014-0097"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_004_w2aab2b8c69b1b7b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Ferraro S, Schiumarini D, Panteghini M. Human epididymis proten 4: factors of variation. Clin Chim Acta 2014;438:171\u20137.","DOI":"10.1016\/j.cca.2014.08.020"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_005_w2aab2b8c69b1b7b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Ferraro S, Borille S, Caruso S, Boggio A, Muzio F, Rizzi A, et al. Body mass index does not influence human epididymis protein 4 concentrations in serum. Clin Chim Acta 2015;446:163\u20134.","DOI":"10.1016\/j.cca.2015.04.028"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_006_w2aab2b8c69b1b7b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Kappelmayer J, Antal-Szalm\u00e1s P, Nagy B Jr. Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders. Clin Chim Acta 2015;438:35\u201342.","DOI":"10.1016\/j.cca.2014.07.040"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_007_w2aab2b8c69b1b7b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Gizzo S, Ancona E, Saccardi C, D\u2019Antona D, Nardelli GB, Plebani M. Could kidney glomerular filtration impairment represent the \u201cAchilles heel\u201d of HE4 serum marker? A possible further implication. Clin Chem Lab Med 2014;52:e45\u20136.","DOI":"10.1515\/cclm-2013-0660"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_008_w2aab2b8c69b1b7b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57:1534\u201344.","DOI":"10.1373\/clinchem.2010.157073"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_009_w2aab2b8c69b1b7b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med 2012;50:2181\u20138.","DOI":"10.1515\/cclm-2012-0097"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_010_w2aab2b8c69b1b7b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Nagy B Jr, Krasznai ZT, Balla H, Csob\u00e1n M, Antal-Szalm\u00e1s P, Hern\u00e1di Z, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem 2012;49:377\u201380.","DOI":"10.1258\/acb.2011.011258"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_011_w2aab2b8c69b1b7b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Bolstad N, \u00d8ijordsbakken M, Nustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol 2012;33:141\u20138.","DOI":"10.1007\/s13277-011-0256-4"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_012_w2aab2b8c69b1b7b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847\u201353.","DOI":"10.1038\/modpathol.3800612"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_013_w2aab2b8c69b1b7b1ab2b2c13Aa","unstructured":"Romeo V, Framarino Dei Malatesta M, Nudo F, Simonelli L, Derme M, Berloco PB. Is HE4 serum level a valid screening test in women candidates for kidney transplant? A case report and a review of literature. Clin Ter 2014;165:e162\u20135."},{"key":"2023033109501727150_j_cclm-2015-1272_ref_014_w2aab2b8c69b1b7b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Lindquist JA, Mertens PR. Myofibroblasts, regeneration or renal fibrosis \u2013 Is there a decisive hint? Nephrol Dial Transplant 2013;28:2678\u201381.","DOI":"10.1093\/ndt\/gft247"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_015_w2aab2b8c69b1b7b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Lv YW, Yang L, Zhang M, Jiang LH, Niu JH, Hou J, et al. Increased human epididymis protein 4 in benign gynecological diseases complicated with chronic renal insufficiency patients. Genet Mol Res 2015;14:2156\u201361.","DOI":"10.4238\/2015.March.27.2"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_016_w2aab2b8c69b1b7b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Allison SJ. Fibrosis: HE4 \u2013 A biomarker and target in renal fibrosis. Nat Rev Nephrol 2013;9:124.","DOI":"10.1038\/nrneph.2013.2"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_017_w2aab2b8c69b1b7b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"LeBleu VS, Teng Y, O\u2019Connell JT, Charytan D, M\u00fcller GA, M\u00fcller CA, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med 2013;19: 227\u201331.","DOI":"10.1038\/nm.2989"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_018_w2aab2b8c69b1b7b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"de Jonge MJ, Verweij J. Renal toxicities of chemotherapy. Semin Oncol 2006;33:68\u201373.","DOI":"10.1053\/j.seminoncol.2005.11.011"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_019_w2aab2b8c69b1b7b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 2000;46:193\u20137.","DOI":"10.1093\/clinchem\/46.2.193"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_020_w2aab2b8c69b1b7b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Ferraro S, Marano G, Biganzoli EM, Boracchi P, Bongo AS. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med 2011;49:1397\u2013404.","DOI":"10.1515\/CCLM.2011.607"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_021_w2aab2b8c69b1b7b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604\u201312.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_022_w2aab2b8c69b1b7b1ab2b2c22Aa","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Supp 2013;3:1\u2013150."},{"key":"2023033109501727150_j_cclm-2015-1272_ref_023_w2aab2b8c69b1b7b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Yang J, Sa M, Huang M, Yang J, Xiang Z, Liu B, et al. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay. Clin Biochem 2013;46:1705\u20138.","DOI":"10.1016\/j.clinbiochem.2013.08.019"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_024_w2aab2b8c69b1b7b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Ferraro S, Borille S, Carnevale A, Frusciante E, Bassani N, Panteghini M. Verification of the harmonization of human epididymis protein 4 assays. Clin Chem Lab Med 2016;54:1635\u201343.","DOI":"10.1515\/cclm-2015-1142"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_025_w2aab2b8c69b1b7b1ab2b2c25Aa","unstructured":"www.r-project.org. Accessed: 17 Nov 2015."},{"key":"2023033109501727150_j_cclm-2015-1272_ref_026_w2aab2b8c69b1b7b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Costongs GM, Janson PC, Bas BM, Hermans J, van Wersch JW, Brombacher PJ. Short-term and long-term intra-individual variations and critical differences of clinical chemical laboratory parameters. J Clin Chem Clin Biochem 1985;23:7\u201316.","DOI":"10.1515\/cclm.1985.23.7.405"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_027_w2aab2b8c69b1b7b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Meeusen JW, Rule AD, Voskoboev N, Baumann NA, Lieske JC. Performance of cystatin C- and creatinine-based estimated glomerular filtration rate equations depends on patient characteristics. Clin Chem 2015;61:1265\u201372.","DOI":"10.1373\/clinchem.2015.243030"},{"key":"2023033109501727150_j_cclm-2015-1272_ref_028_w2aab2b8c69b1b7b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Levey AS, Eckfeldt JH. Using glomerular filtration rate estimating equations: clinical and laboratory considerations. Clin Chem 2015;61:1226\u20139.","DOI":"10.1373\/clinchem.2015.245282"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2016.54.issue-10\/cclm-2015-1272\/cclm-2015-1272.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1272\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:08:49Z","timestamp":1680257329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1272\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,5,11]]},"published-print":{"date-parts":[[2016,10,1]]}},"alternative-id":["10.1515\/cclm-2015-1272"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2015-1272","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}